Sun.Mar 03, 2024

article thumbnail

Understanding and Supporting Male Postpartum Depression

Pharma Mirror

Presented by BetterHelp. Some people still aren’t aware that men and non-gestational parents can also experience emotional dysregulation after the birth of a child. Luckily, the conversation surrounding women and gestational parents and postpartum depression has gained a lot of awareness. However, are we forgetting the other half of the parenting dyad?

Hormones 130
article thumbnail

Keeping Your Company’s Federal Contracting Options Safe in the Face of Pending BIOSECURE Act Legislation

FDA Law Blog

By Steven J. Gonzalez & JP Ellison — The most recent version of the BIOSECURE Act (the “Act”) was introduced in the U.S. House of Representatives ( H.B. 7085 ) and Senate ( S.B. 3558 ) on January 25, 2024. This proposed legislation should be of interest to any biotechnology companies that want to do business with the federal government in the future.

Genome 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RNA therapy firm Avidity files $400m placement

pharmaphorum

Avidity Biosciences files $400m private placement as it prepares for phase 3 trial of lead antibody oligonucleotide conjugate AOC 1001 in rare disease DM1

RNA 91
article thumbnail

Dementia Prevention and Treatment

JAMA Internal Medicine

This Narrative Review summarizes current evidence and explores emerging science on the prevention and treatment of dementia to inform clinical decision-making.

75
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Judge knocks back AstraZeneca’s IRA challenge

pharmaphorum

Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug pricing negotiation under the Inflation Reduction Act

Drugs 82
article thumbnail

The LDT Rule Takes Another Step to Finalization — and a Likely Lawsuit

FDA Law Blog

By Jeffrey N. Gibbs & Allyson B. Mullen — FDA’s proposed rule to regulate laboratory developed tests (LDTs) as devices took one more step towards being finalized – and to a likely judicial showdown. On March 1, the Office of Management and Budget (OMB) received the draft final LDT rule for review ( here ). The LDT rule has moved forward with astonishing speed, advancing from the release of the proposed rule on October 3, 2023 to OMB in less than five months.

More Trending

article thumbnail

Which pharmaceutical drugs have the most drug patents in Ukraine?

Drug Patent Watch

This chart shows the drugs with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 104
article thumbnail

I Am Worried About Memory Loss—What Should I Know?

JAMA Internal Medicine

This JAMA Internal Medicine Patient Page describes memory loss and dementia and how they may be treated.

article thumbnail

Complication Rates of Central Venous Catheters

JAMA Internal Medicine

This systematic review and meta-analysis summarizes current rates of central venous catheter–associated complications.

52
article thumbnail

Longitudinal Management of Dementia in Primary Care

JAMA Internal Medicine

This Viewpoint describes the positive role that primary care teams can play in the lives of patients with dementia and the families that care for them.

40
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations